Pharmafile Logo

Galimedix Therapeutics

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD 2025 Conference

Data show positive impact of small molecule GAL-201 on Aβ-induced toxicity, caused by various Aβ isoforms: beneficial effects on synaptic plasticity and neuroinflammation 24 March 2025 — Maryland, US and Munich/Martinsried, Germany — Galimedix Therapeutics, Inc, a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the…

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference

Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 — Maryland, US — Galimedix Therapeutics, a phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionise the treatment of serious eye and…
https://galimedix.com/
info@galimedix.com
3704 Calvend Lane Kensington, MD 20895 USA